Incyte 与 Genesis 宣布扩大双方的战略合作

WILMINGTON, Del.&SAN MATEO, Calif.--(BUSINESS WIRE)--May 20, 2026-- Incyte (Nasdaq:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected byIncyte. The expanded agreement is among the first major pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520680248/en/

Building on the companies' initial collaboration announced inFebruary 2025, the expanded agreement broadens the deployment of Genesis’ AI platform, GEMS (Genesis Exploration of Molecular Space) – which includes the leading foundation models for protein-ligand structure and property prediction – across a wider variety of challenging targets in Incyte’s portfolio.Incytewill also share proprietary experimental data with Genesis to enhance GEMS’ capabilities.

“This expanded collaboration reflects the strong results from our initial programs and Incyte’s commitment to applying advanced technologies to enhance our discovery engine and accelerate the development of differentiated small molecule medicines,” saidPablo J. Cagnoni, M.D., President,Incyteand Global Head of R&D. “By combining our deep expertise in drug discovery and development and our significant experimental data with Genesis' AI capabilities, we aim to more efficiently advance priority programs against high-value targets and ultimately bring important new medicines to patients."

“Our partnership withIncytereflects the exciting synergy between our AI platform and Incyte’s deep expertise and capabilities in rapid experimental data generation and marks an important moment in the evolution of AI in this vertical,” saidEvan Feinberg, Ph.D., Founder and Chief Executive Officer of Genesis. “High-quality proprietary data is among the most valuable inputs for advancing molecular AI, and our expanded collaboration will enable both companies and patients to benefit from an industrial-scale flywheel of AI-enabled design-make-test cycles."

Terms of the Agreement

Genesis will receive total upfront consideration of$120 million, which includes an$80 millionupfront cash payment and a$40 millionpurchase of equity in Genesis. In addition,Incytewill also provide recurring research funding to Genesis to support AI model training and inference compute workloads.

The companies will add at least five new collaboration targets selected byIncyte, andIncytewill have options to nominate additional collaboration targets over time.Incytewill have exclusive rights to develop and commercialize any collaboration products.

Genesis will be eligible to receive potential preclinical and clinical development, regulatory and sales milestone payments of up to$232 millionfor each program contingent on the achievement of agreed upon milestones. Genesis will be eligible to receive over$1 billionif all milestones are achieved across the five initial collaboration targets, including multiple indications and major territories, provided the aggregate peak annual net sales of the five products exceed specified milestones. Additional payments totaling several billion dollars could be earned depending on the number of additional collaboration targets nominated and the achievement of related milestones. Genesis is also eligible to receive royalties on sales of any approved collaboration products.